CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
323U66 SRdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00330616
NCT00330616Phase 2Completed
CompareCT.gov

Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression

GlaxoSmithKline·interventional·Posted May 29, 2006·Updated May 4, 2015

In Brief

A Phase 2 clinical trial evaluating 323U66 SR for Major Depressive Disorder (MDD). Completed, enrolled 35 participants across 9 sites.

Detailed Summary

This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics profile in elderly patients with depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder (MDD)
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 29, 2006
Enrollment StartMay 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.1 years ago

Interventions

323U66 SRdrug